Status:
ACTIVE_NOT_RECRUITING
Angiotensin-(1-7) and Energy Expenditure in Human Obesity
Lead Sponsor:
Amy Arnold
Conditions:
Obesity
Eligibility:
All Genders
18-60 years
Phase:
EARLY_PHASE1
Brief Summary
The objective of this study is to better define the role of the hormone angiotensin-(1-7) in energy balance. We will test the overall hypothesis that angiotensin-(1-7) increases resting energy expendi...
Detailed Description
Angiotensin-(1-7) is a beneficial hormone of the renin-angiotensin system known to produce positive cardiovascular and metabolic effects in animal models. In this study, the investigators will determi...
Eligibility Criteria
Inclusion
- Men and women of all races
- Capable of giving informed consent
- Age 18-60 years
- Body mass index (BMI) between 30-40 kg/m2
- Satisfactory history and physical exam
Exclusion
- Age ≤ 17 or ≥ 61 years
- Pregnant, nursing, or postmenopausal women
- Decisional impairment
- Prisoners
- Alcohol or drug abuse
- Current smokers
- Highly trained athletes
- Claustrophobia
- Subjects with \>5% weight change in the past 3 months
- Evidence of type I or type II diabetes (fasting glucose \> 126 mg/dL or use of anti-diabetic medications)
- History of serious cardiovascular disease other than hypertension (e.g. myocardial infarction within 6 months, symptomatic coronary artery disease, presence of angina pectoris, significant arrhythmia, congestive heart failure, deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, hypertrophic cardiomyopathy) or cerebrovascular disease (e.g. cerebral hemorrhage, stroke, transient Ischemic attack).
- History or presence of immunological or hematological disorders
- Impaired hepatic function (aspartate aminotransferase or alanine aminotransferase levels \>2 times upper limit of normal range)
- Impaired renal function (serum creatinine \>2.0 mg/dl)
- Anemia
- Treatment with anticoagulants (e.g. warfarin)
- Treatment with chronic systemic glucocorticoid therapy (\>7 consecutive days in 1 month)
- Treatment with medications influencing energy expenditure (e.g. psychostimulants)
- Treatment with any investigational drug in the 1-month preceding the study
- Inability to give, or withdraw, informed consent
Key Trial Info
Start Date :
September 26 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03777215
Start Date
September 26 2019
End Date
December 1 2026
Last Update
September 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States, 17033